X
Novartis backs brolucizumab with new head-to-head Eylea trial
https://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/
Lucentis
Novartis to buy ophthalmology firm Encore Vision
Swiss pharma buys treatment for common age-related vision problem.
Eleven seals deal with Roche on eye drug pipeline
Deal helps biotech to move on from phase 3 failures